628 related articles for article (PubMed ID: 27040772)
21. MicroRNA alteration and putative target genes in high-grade prostatic intraepithelial neoplasia and prostate cancer: STAT3 and ZEB1 are upregulated during prostate carcinogenesis.
Cha YJ; Lee JH; Han HH; Kim BG; Kang S; Choi YD; Cho NH
Prostate; 2016 Jul; 76(10):937-47. PubMed ID: 27017949
[TBL] [Abstract][Full Text] [Related]
22. Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality.
Naik M; Reddy CA; Stephans KL; Ciezki JP; Garcia J; Grivas P; Stephenson AJ; Klein EA; Tendulkar RD
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):617-23. PubMed ID: 27681757
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive study of gene and microRNA expression related to epithelial-mesenchymal transition in prostate cancer.
Katz B; Reis ST; Viana NI; Morais DR; Moura CM; Dip N; Silva IA; Iscaife A; Srougi M; Leite KR
PLoS One; 2014; 9(11):e113700. PubMed ID: 25409297
[TBL] [Abstract][Full Text] [Related]
24. Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy.
Huang SP; Bao BY; Wu MT; Choueiri TK; Goggins WB; Liu CC; Huang CY; Pu YS; Yu CC; Wu TT; Huang CN; Huang CH; Wu WJ
Aging Male; 2012 Mar; 15(1):34-41. PubMed ID: 21615239
[TBL] [Abstract][Full Text] [Related]
25. Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy.
Wang Y; Xu F; Pan J; Zhu Y; Shao X; Sha J; Wang Z; Cai Y; Liu Q; Dong B; Xue W; Huang Y
BMC Cancer; 2016 May; 16():329. PubMed ID: 27222030
[TBL] [Abstract][Full Text] [Related]
26. Overexpressed Rce1 is positively correlated with tumor progression and predicts poor prognosis in prostate cancer.
Huang L; Li M; Wang D; He J; Wu W; Zeng Q; Li J; Xiao M; Hu J; He Y; Li Y; Mai L; Liu W
Hum Pathol; 2016 Jan; 47(1):109-14. PubMed ID: 26546252
[TBL] [Abstract][Full Text] [Related]
27. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
Leidinger P; Hart M; Backes C; Rheinheimer S; Keck B; Wullich B; Keller A; Meese E
Tumour Biol; 2016 Aug; 37(8):10177-85. PubMed ID: 26831660
[TBL] [Abstract][Full Text] [Related]
28. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
29. Tissue microRNA-126 expression level predicts outcome in human osteosarcoma.
Liu W; Zhao ZY; Shi L; Yuan WD
Diagn Pathol; 2015 Jul; 10():116. PubMed ID: 26194657
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of transformer 2β expression in prostate cancer.
Diao Y; Wu D; Dai Z; Kang H; Wang Z; Wang X
Int J Clin Exp Pathol; 2015; 8(6):6967-73. PubMed ID: 26261585
[TBL] [Abstract][Full Text] [Related]
31. Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy.
Tomioka A; Tanaka N; Yoshikawa M; Miyake M; Anai S; Chihara Y; Okajima E; Hirayama A; Hirao Y; Fujimoto K
BMC Cancer; 2015 May; 15():420. PubMed ID: 25990314
[TBL] [Abstract][Full Text] [Related]
32. Aberrant expression of microRNA-26b and its prognostic potential in human cervical cancer.
Luo M; Shen D; Wang W; Xian J
Int J Clin Exp Pathol; 2015; 8(5):5542-8. PubMed ID: 26191262
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA expression signature of castration-resistant prostate cancer: the microRNA-221/222 cluster functions as a tumour suppressor and disease progression marker.
Goto Y; Kojima S; Nishikawa R; Kurozumi A; Kato M; Enokida H; Matsushita R; Yamazaki K; Ishida Y; Nakagawa M; Naya Y; Ichikawa T; Seki N
Br J Cancer; 2015 Sep; 113(7):1055-65. PubMed ID: 26325107
[TBL] [Abstract][Full Text] [Related]
34. Serum microRNA-221 functions as a potential diagnostic and prognostic marker for patients with osteosarcoma.
Yang Z; Zhang Y; Zhang X; Zhang M; Liu H; Zhang S; Qi B; Sun X
Biomed Pharmacother; 2015 Oct; 75():153-8. PubMed ID: 26422796
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of ETS-1 is associated with malignant biological features of prostate cancer.
Li B; Shimizu Y; Kobayashi T; Terada N; Yoshimura K; Kamba T; Mikami Y; Inoue T; Nishiyama H; Ogawa O
Asian J Androl; 2012 Nov; 14(6):860-3. PubMed ID: 23064684
[TBL] [Abstract][Full Text] [Related]
36. Increased expression of microRNA-196a predicts poor prognosis in human ovarian carcinoma.
Fan Y; Fan J; Huang L; Ye M; Huang Z; Wang Y; Li Q; Huang J
Int J Clin Exp Pathol; 2015; 8(4):4132-7. PubMed ID: 26097603
[TBL] [Abstract][Full Text] [Related]
37. Periprostatic Fat Thickness on MRI is an Independent Predictor of Time to Castration-resistant Prostate Cancer in Chinese Patients With Newly Diagnosed Prostate Cancer Treated With Androgen Deprivation Therapy.
Huang H; Chen S; Li W; Bai P; Wu X; Xing J
Clin Genitourin Cancer; 2019 Oct; 17(5):e1036-e1047. PubMed ID: 31281063
[TBL] [Abstract][Full Text] [Related]
38. Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy.
Alsinnawi M; Zhang A; Bianchi-Frias D; Burns J; Cho E; Zhang X; Sowalsky A; Ye H; Slee AE; True L; Porter C; Taplin ME; Balk S; Nelson PS; Montgomery RB; Mostaghel EA
Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):560-568. PubMed ID: 30890759
[TBL] [Abstract][Full Text] [Related]
39. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
40. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]